Sun Pharma Q2 FY27 Earnings Call Transcript Released
Sun Pharma reported Q2 FY27 consolidated sales of INR 1,61,000 million, up 11.8%. EBITDA stood at INR 47,439 million. The company's India formulations business grew 17.3%. Innovative Medicines sales rose 6.9% to USD 356 million. The Organon acquisition remains on track for early 2027 closure.
The announcement provides detailed financial results for the quarter, including key metrics like sales, gross margin, EBITDA, and net profit, which are material to investors. Updates on strategic initiatives like the Organon acquisition and product launches also have a significant impact.
The company reported strong sales growth in Q2 FY27, with significant increases in both consolidated sales and the India formulations business. Positive updates on the Organon acquisition and innovative medicines pipeline also contribute to a positive sentiment.
Sun Pharmaceutical Industries Limited has released the transcript of its Q2 FY27 earnings conference call. The call, which took place on October 30, 2026, at 06:30 pm, featured insights from Chairman Dilip Shanghvi, Managing Director Kirti Ganorkar, CFO Jayashree Satagopan, and CEO North America Richard Ascroft.
During the quarter, consolidated sales reached INR 1,61,000 million (USD 161 billion), marking an 11.8% growth year-over-year. Gross margin stood at 80.8%, with EBITDA at INR 47,439 million (USD 47.4 billion), a 4.8% increase. Reported net profit after tax was INR 19,885 million (USD 19.8 billion), while adjusted net profit was INR 31,620 million (USD 31.6 billion).
The company noted that the Organon acquisition is on track to close by early 2027, subject to closing conditions. For the first half of FY27, sales grew by 11% to INR 3,12,836 million (USD 312.8 billion), with EBITDA at INR 91,616 million (USD 91.6 billion).
Global Innovative Medicines sales increased by 6.9% to USD 356 million, driven by growth in Ilumya and Cequa. Ilumya received US approval for psoriatic arthritis and is planned for a soft launch in November. The India formulations business saw a significant 17.3% growth, reaching INR 55,523 million (USD 55.5 billion), with Sun Pharma holding an 8.6% market share. US business sales were USD 455 million, a 8.2% decline primarily due to lenalidomide erosion, though quarter-over-quarter growth was 6.5%. R&D investments for Q2 FY27 were INR 7,784 million (USD 7.7 billion), representing 4.8% of sales, with innovative R&D accounting for 32.4% of the total spend. The company reiterated its full-year guidance for R&D spend.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.